BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21181317)

  • 1. MR imaging of triple-negative breast cancer.
    Uematsu T
    Breast Cancer; 2011 Jul; 18(3):161-4. PubMed ID: 21181317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple-negative breast cancer: correlation between MR imaging and pathologic findings.
    Uematsu T; Kasami M; Yuen S
    Radiology; 2009 Mar; 250(3):638-47. PubMed ID: 19244039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Breast cancer subtypes based on ER/PR and Her2 expression: comparison of MR imaging features].
    Hao L; Yu RS; Cui F; Ren XC; Xu HB; Xu KY
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(11):819-23. PubMed ID: 23859386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathologic features and prognosis of triple negative breast cancer].
    Zhou T; Yang L; Ma GM; Li CX; Bai Y; Zhao JA; Wang XL; Geng CZ
    Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2261-4. PubMed ID: 20095338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research and progress in magnetic resonance imaging of triple-negative breast cancer.
    Li J; Han X
    Magn Reson Imaging; 2014 May; 32(4):392-6. PubMed ID: 24512798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic triple-negative breast cancer.
    Rakha EA; Chan S
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):587-600. PubMed ID: 21524569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Current status and future perspectives for the treatment of triple-negative breast cancer in Japan].
    Masuda N; Yasojima H; Mizutani M; Yamamura J
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):512-8. PubMed ID: 22504674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
    Lara-Medina F; Pérez-Sánchez V; Saavedra-Pérez D; Blake-Cerda M; Arce C; Motola-Kuba D; Villarreal-Garza C; González-Angulo AM; Bargalló E; Aguilar JL; Mohar A; Arrieta Ó
    Cancer; 2011 Aug; 117(16):3658-69. PubMed ID: 21387260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance (MR) features in triple negative breast cancer (TNBC) vs receptor positive cancer (nTNBC).
    Angelini G; Marini C; Iacconi C; Mazzotta D; Moretti M; Picano E; Morganti R
    Clin Imaging; 2018; 49():12-16. PubMed ID: 29120811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Among triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results.
    Nakagawa M; Bando Y; Nagao T; Takai C; Ohnishi T; Honda J; Moriya T; Izumi K; Takahashi M; Tangoku A; Sasa M
    Breast Cancer; 2012 Jan; 19(1):54-9. PubMed ID: 21465226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic resonance imaging of breast cancer and correlation with prognostic factors.
    Chang YW; Kwon KH; Choi DL; Lee DW; Lee MH; Lee HK; Yang SB; Kim Y; Seo DY
    Acta Radiol; 2009 Nov; 50(9):990-8. PubMed ID: 19863408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.
    Youk JH; Son EJ; Chung J; Kim JA; Kim EK
    Eur Radiol; 2012 Aug; 22(8):1724-34. PubMed ID: 22527371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of triple negative breast cancer (TNBC): current options and future perspectives.
    De Laurentiis M; Cianniello D; Caputo R; Stanzione B; Arpino G; Cinieri S; Lorusso V; De Placido S
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S80-6. PubMed ID: 21129616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatment options in triple negative breast cancer.
    Rodler E; Korde L; Gralow J
    Breast Dis; 2010; 32(1-2):99-122. PubMed ID: 21778572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.
    Flowers A; Chu QD; Panu L; Meschonat C; Caldito G; Lowery-Nordberg M; Li BD
    Surgery; 2009 Aug; 146(2):220-6. PubMed ID: 19628077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the difference between triple-negative and basal breast cancers?
    Seal MD; Chia SK
    Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.